Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone*
Authors:
- Carol Braun TrapnellCTCarol Braun Trapnell
- Stephen R. DonahueSDStephen R. Donahue
- Jerry M. CollinsJCJerry M. Collins
- David A. FlockhartDFDavid A. Flockhart
- David ThackerDTDavid Thacker
- Darrell R. AbernethyDADarrell R. Abernethy
- 1 December 1998
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 64 (6) , 597-602
Abstract
To evaluate the effect of thalidomide on the plasma pharmacokinetics of ethinyl estradiol (INN, ethinylestradiol) and norethindrone (INN, norethisterone). Ten women who had undergone surgical sterilization were enrolled in an open-label crossover study conducted in the Georgetown University Clinical Research Center. The pharmacokinetics of single doses of 0.07 mg ethinyl estradiol and 2 mg norethindrone were measured at baseline and after 3 weeks of 200 mg thalidomide. Compliance with the thalidomide regimen was assessed with use of Medication Event Monitoring System (MEMS) caps. No changes were observed in the pharmacokinetics of ethinyl estradiol or norethindrone with thalidomide therapy. The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05). The values for norethindrone were 103 +/- 54 micrograms.h/L and 107 +/- 58 micrograms.h/L (paired t test, P > .05). No changes were observed for other pharmacokinetic parameters assessed for either ethinyl estradiol or norethindrone. No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05). No changes were observed for other pharmacokinetic parameters assessed for thalidomide between days 1 and 21. Thalidomide was well tolerated but caused variable degrees of sedation. The average thalidomide compliance rate was 97%. The pharmacokinetics of thalidomide do not change with 3 weeks of daily dosing. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol or norethindrone. Therefore there is no drug interaction between thalidomide and these 2 drugs. The efficacy of oral contraceptives containing ethinyl estradiol and norethindrone should not be affected by concomitant thalidomide therapy.Keywords
This publication has 19 references indexed in Scilit:
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Angiogenesis Research Enjoys Growth Spurt in the 1990sJNCI: Journal of the National Cancer Institute, 1996
- Development of a highly sensitive and specific assay for plasma ethinylestradiol using combined extraction, liquid chromatography and radioimmunoassayJournal of Pharmaceutical and Biomedical Analysis, 1994
- Clinically Significant Drug Interactions with Antituberculosis AgentsDrug Safety, 1994
- Graft-versus-host diseaseCurrent Opinion in Oncology, 1994
- The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum LeprosumThe Journal of Infectious Diseases, 1993
- Oral ContraceptivesDrug Safety, 1993
- Thalidomide in Human Immunodeficiency Virus (HIV) PatientsDrug Safety, 1992
- Determination of Ethinylestradiol and Norethindrone in a Single Specimen of Plasma by Automated High-Performance Liquid Chromatography and Subsequent RadioimmunoassayJournal of Liquid Chromatography, 1987
- Variability of pharmacokinetic parameters for contraceptive steroidsJournal of Steroid Biochemistry, 1983